X

Drug Profile

ALLO 329

Alternative Names: ALLO-329

Latest Information Update: 09 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Allogene Therapeutics
Class CAR-T cell therapies; Gene therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Systemic lupus erythematosus

Most Recent Events

31 Mar 2024 Allogene Therapeutics announces intention to submit NDA to US FDA for Autoimmune Disease in first quarter of 2024
05 Jan 2024 Preclinical trials in Systemic lupus erythematosus in USA (Parenteral) before January 2023
04 Jan 2024 Allogene Therapeutics plans a phase I trial for Systemic lupus erythematosus in early 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com